Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
Phase 4 N=20 Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Kidney Transplant
Primary: Graft Survival — 13; 7 participants — p=0.849
Phase 3 N=852 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Kidney Transplantation
Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
Phase 4 N=36 Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Number of Subjects With a Perfusion Defect — 5; 6 Participants
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 4 N=30 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Renal Transplant Rejection · Immunosuppression
Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 3 N=709 Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Kidney Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) — 64.1; 61.5; 58.4 mL/min/1.73m^2
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 4 N=52 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Kidney Transplantation
Primary: Number of Participants With Graft Survival at 12 Months — 18; 12 Participants
Phase 4 N=341 Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
Renal Function
Primary: Measured Glomerular Filtration Rate — 51.5; 47.8 mL/min/1.73m^2
Phase 3 N=78 REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
Liver Transplantation
Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013
Phase 4 N=120 Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Cardiorenal Syndrome · Chronic Allograft Nephropathy
Primary: CAD (Chronic Allograft Dysfunction) Degree — 1.24; 1.22; 1.43; 1.68 Scores on a Banff scale — p=<0.05
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
Phase 2 N=33 CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Cardiorenal Syndrome (CRS)
Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Phase 1 N=16 Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Phase 4 N=394 ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
Renal Transplantation
Primary: Renal Function Assessed by Measured GFR (mGFR) — 46.02; 48.00; 46.60 mL/min/1.73m^2 — p=0.6332
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Phase 3 N=203 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Liver Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) — 87.9; 84.1 mL/min
N/A N=128 An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
Kidney Transplantation
Primary: Creatinine Clearance at 1 Month After Transplantation — 65.82 mL/min
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
N/A N=24 Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
Immunosuppression · Renal Failure
Primary: Renal Function as Measured by 24 Hour Urine Creatinine Clearance — 68.09; 70.75; 68.09; 86.8 mL/min